RAS genes and cancer

Tikvah K. Hayes, Jeran K. Stratford, Andrea Wang-Gillam, Channing J. Der

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The three RAS genes (HRAS, KRAS, and NRAS) comprise the most commonly mutated oncogene family in human cancer. RAS genes encode highly related small GTPases that are key regulators of cytoplasmic signaling networks that include the Raf-MEK-ERK mitogen-activated protein kinase cascade and the PI3K-Akt signaling cascade. There is increasing evidence that all RAS mutations are not created equal and that mutation specific therapies may be needed, that there will not be a one size fits all anti-Ras therapy. In this chapter, we summarize the frequency and nature of RAS mutations in human cancers, with a focus on the two cancers with the highest frequency of RAS mutations, pancreatic ductal adenocarcinoma (95 %), and colorectal (40 %) cancers.

Original languageEnglish
Title of host publicationRas Superfamily Small G Proteins
Subtitle of host publicationBiology and Mechanisms 1: General Features, Signaling
PublisherSpringer-Verlag Wien
Number of pages15
ISBN (Electronic)9783709118061
ISBN (Print)3709118050, 9783709118054
StatePublished - May 1 2014


  • Colorectal cancer
  • ERK
  • HRAS
  • KRAS
  • NRAS
  • PI3K
  • Pancreatic cancer
  • Raf


Dive into the research topics of 'RAS genes and cancer'. Together they form a unique fingerprint.

Cite this